~~<i id='7973251DF7'><strike id='7973251DF7'><tt id='7973251DF7'><pre id='7973251DF7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：fashion 2025-09-30 00:09:37 - browse：523

Blue nerve cell surrounded by red antibodies. -- health coverage from STAT — Adobe

Belgian drugmaker Argenx said Monday that its antibody treatment called Vyvgart significantly delayed the progression of an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.

The positive outcome — a 61% reduction in the risk of relapse compared to a placebo — achieved the main goal of a Phase 3 clinical trial designed to demonstrate Vyvgart’s benefit for patients with chronic inflammatory demyelinating polyneuropathy, or CIDP.

“We hit the bullseye,” said Argenx CEO Tim Van Hauwermeiren.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Bristol 'take

focus

hotspot

entertainment

focus

DanSkovronsky,EliLilly'schiefscientificofficer,atthe2023STATSummit.STATPHILADELPHIA—Inasense,theannu

WSS

A letter from the executive editor: STAT UnitedHealth investigation

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Ventyx halts psoriasis drug development after lackluster trial results

Medical school prerequisites are outdated

Histogen: Failed biotech offers rare public look inside

focus

leisure time

focus

Medicare details structure of new drug price negotiation program

Chemotherapy drug shortage eases slightly but still widespread

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What health policies could hitch a ride on a spending bill?

Medical records are filled with copy

Ohio still needs to do more to protect the right to abortion

Duchenne breakthrough therapy leaves behind pioneering families

After decades in use, heart stents finally beat placebo

In Memoriam: Notable people who died in 2023

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

focus

Ohio still needs to do more to protect the right to abortion

What is STAT's opinion section for?

What health policies could hitch a ride on a spending bill?

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Healthy food access boosts outcomes in two studies

FDA reorg will put new emphasis on investigations, sources say

hotspot

entertainment

focus

focus